HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 52.2%

Neg 0% Neu 52.2% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and announces $6 price target.